Even More on Prescription Drugs
Michael Williams has some good comments as follow-up to my two post below on patents and drug prices (scroll down). One clarification: if the patent expiration clock was not started until FDA approval, I'd favor a patent length of something less than 17 years. A guaranteed seven full years, perhaps - plenty of time I'd think for drug makers to recoup their R&D costs and make a profit.

UPDATE: Steven Antler over at EconoPundit has a look at the prescription drug subsidy plan now working its way through Congress and who it is really gonna help. Antler provides a link to and commentary on a National Center for Policy Analysis summary of a New York Times article (!) thhat questions whether the plan will really be of much help to many seniors. Antler: "Two thirds of the elderly have drug costs lower than $92 per month. (Uh, maybe this isn't quite the crisis we thought it was?)" Follow the links. And do yourself a favor and add EconoPundit to your blogroll or list of bookmarked sites to check frequently.

And Donald Sensing has commentary on and a link to a rather fine column in the Rocky Mountain News by University of Colorado law professor Paul Campos, on the prescription drug plan as a "$400 billion bribe" to buy votes. Good reading, all.